Cargando…

30 years of HIV: what have we learned?

I saw my first patient with severe immune deficiency in 1979 – a very low CD4 count had been noted, but it was not until the first reports of an epidemic occurred in 1981 that the correct diagnosis was made. Subsequently, I have seen more than 15,000 patients with HIV-related immune deficiency, and...

Descripción completa

Detalles Bibliográficos
Autor principal: Gazzard, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224818/
https://www.ncbi.nlm.nih.gov/pubmed/25393987
http://dx.doi.org/10.7448/IAS.17.4.19478
_version_ 1782343411630604288
author Gazzard, Brian
author_facet Gazzard, Brian
author_sort Gazzard, Brian
collection PubMed
description I saw my first patient with severe immune deficiency in 1979 – a very low CD4 count had been noted, but it was not until the first reports of an epidemic occurred in 1981 that the correct diagnosis was made. Subsequently, I have seen more than 15,000 patients with HIV-related immune deficiency, and my life has changed from helping terminally ill patients to die with dignity, in the early part of the epidemic to now providing drugs for an eminently treatable condition – a true miracle. I have a number of observations about the epidemic. Firstly, the courage with which many young people faced death and disablement was truly awe inspiring, and was the chief reason many of the earlier doctors treating these patients stayed in the field. Secondly, the role of activists was overwhelmingly positive forcing the epidemic to the top of the scientific and political agenda and keeping it there. It is also important that activism helped move an ethical agenda reducing the stigma of HIV infection and producing a liberal legal framework which allowed testing and treatment to be acceptable. The right of the world population to health as espoused by Jonathan Mann and others is also crucial. Thirdly, the combination of academic research, activist pressure (and scientific input) and mammon in the form of the pharmaceutical industry acting in concert produced knowledge which led to effective treatment in a breathtakingly short time. Particular tribute in my mind needs to be paid to the pharmaceutical companies in this regard. I believe that the scientific achievements of HIV research illustrate two things. First, science builds from one generation to the next and most (but not all of us) need to be humble about our personal contribution. Second, HIV treatment illustrates the primacy of well conducted randomized control trials. While cohort studies can add to our detailed knowledge of the epidemic, randomised controlled trials remain the cornerstone of most major advances. Fourthly, when human beings act in concert towards a common goal, amazing things can be achieved. In the late 1990s, the possibility of treatment for the millions of people with HIV in the developing world was seen as a distant dream. The present situation whilst not perfect is a tribute to individuals, volunteers, government (particularly American government under President Bush) and personal philanthropy (the Bill & Melinda Gates Foundation, and the Clinton Foundation) that have used scientific knowledge to benefit the global population.
format Online
Article
Text
id pubmed-4224818
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-42248182014-11-13 30 years of HIV: what have we learned? Gazzard, Brian J Int AIDS Soc Oral Presentation – Abstract KL3 I saw my first patient with severe immune deficiency in 1979 – a very low CD4 count had been noted, but it was not until the first reports of an epidemic occurred in 1981 that the correct diagnosis was made. Subsequently, I have seen more than 15,000 patients with HIV-related immune deficiency, and my life has changed from helping terminally ill patients to die with dignity, in the early part of the epidemic to now providing drugs for an eminently treatable condition – a true miracle. I have a number of observations about the epidemic. Firstly, the courage with which many young people faced death and disablement was truly awe inspiring, and was the chief reason many of the earlier doctors treating these patients stayed in the field. Secondly, the role of activists was overwhelmingly positive forcing the epidemic to the top of the scientific and political agenda and keeping it there. It is also important that activism helped move an ethical agenda reducing the stigma of HIV infection and producing a liberal legal framework which allowed testing and treatment to be acceptable. The right of the world population to health as espoused by Jonathan Mann and others is also crucial. Thirdly, the combination of academic research, activist pressure (and scientific input) and mammon in the form of the pharmaceutical industry acting in concert produced knowledge which led to effective treatment in a breathtakingly short time. Particular tribute in my mind needs to be paid to the pharmaceutical companies in this regard. I believe that the scientific achievements of HIV research illustrate two things. First, science builds from one generation to the next and most (but not all of us) need to be humble about our personal contribution. Second, HIV treatment illustrates the primacy of well conducted randomized control trials. While cohort studies can add to our detailed knowledge of the epidemic, randomised controlled trials remain the cornerstone of most major advances. Fourthly, when human beings act in concert towards a common goal, amazing things can be achieved. In the late 1990s, the possibility of treatment for the millions of people with HIV in the developing world was seen as a distant dream. The present situation whilst not perfect is a tribute to individuals, volunteers, government (particularly American government under President Bush) and personal philanthropy (the Bill & Melinda Gates Foundation, and the Clinton Foundation) that have used scientific knowledge to benefit the global population. International AIDS Society 2014-11-02 /pmc/articles/PMC4224818/ /pubmed/25393987 http://dx.doi.org/10.7448/IAS.17.4.19478 Text en © 2014 Gazzard B; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oral Presentation – Abstract KL3
Gazzard, Brian
30 years of HIV: what have we learned?
title 30 years of HIV: what have we learned?
title_full 30 years of HIV: what have we learned?
title_fullStr 30 years of HIV: what have we learned?
title_full_unstemmed 30 years of HIV: what have we learned?
title_short 30 years of HIV: what have we learned?
title_sort 30 years of hiv: what have we learned?
topic Oral Presentation – Abstract KL3
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224818/
https://www.ncbi.nlm.nih.gov/pubmed/25393987
http://dx.doi.org/10.7448/IAS.17.4.19478
work_keys_str_mv AT gazzardbrian 30yearsofhivwhathavewelearned